Trial Profile
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants From Birth to < 18 Years of Age With COVID-19
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Remdesivir (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms CARAVAN
- Sponsors Gilead Sciences
- 02 Jun 2023 Status changed from recruiting to completed.
- 14 Feb 2023 Planned End Date changed from 1 Feb 2023 to 1 Jun 2023.
- 14 Feb 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Jun 2023.